CIA
ARCT icon

Capital Impact Advisors’s Arcturus Therapeutics ARCT Stock Holding History

Capital Impact Advisors’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-155,000
Closed -$6.72M – 111
2020
Q4 		$6.72M Buy
155,000
+45,000
+41% +$3.05M 1.65% 16
2020
Q3 		$4.72M Buy
+110,000
New +$5.46M 1.4% 15

Other funds holding ARCT

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank Julius Baer & Co
Bank Julius Baer & Co Zurich, Switzerland $33.2B AUM 25.01% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Impact Advisors's ARCT Position: Q1 2021 in Review

Capital Impact Advisors sold out of Arcturus Therapeutics (ARCT) in Q1 2021, closing a stake of 155,000 shares — an estimated $6.72M sold.

Capital Impact Advisors first reported a position in ARCT in Q3 2020 and held it in 2 quarters. The position peaked at $6.72M in Q4 2020. 162 funds tracked by Wall St. Rank hold ARCT as of Q1 2021.

  • Capital Impact Advisors reported no remaining Arcturus Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Capital Impact Advisors sold 155,000 Arcturus Therapeutics shares in Q1 2021, an estimated $6.72M.
  • Capital Impact Advisors first reported a position in Arcturus Therapeutics in Q3 2020 and held it in 2 quarters.
  • Capital Impact Advisors's Arcturus Therapeutics position peaked at $6.72M in Q4 2020.
  • 162 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q1 2021.

Based on Capital Impact Advisors's 13F filing for Q1 2021, filed 18 May 2021.